Humulin 70/30 is a medication approved for treating diabetes. It contains two different types of insulin (an intermediate-acting insulin and a short-acting insulin) that help control blood sugar levels. The medication comes in injectable form and is typically used twice a day, about half an hour before meals. Potential side effects include injection site skin reaction and low blood sugar.
What Is Humulin 70/30?
Humulin® 70/30 (NPH insulin/regular insulin) is a non-prescription insulin medication used to treat diabetes. It contains a mixture of two different types of insulin, NPH insulin (an intermediate-acting insulin) and regular insulin (a short-acting insulin). Using this combination insulin product decreases the number of injections per day (since it combines two types of insulin in one injection).
Humulin 70/30 is manufactured by Eli Lilly and Company.
How Does It Work?
Insulin is a hormone that is naturally produced by the pancreas. This hormone is important for several functions, such as controlling blood sugar. Insulin helps the cells of your body remove glucose ("sugar") from your bloodstream. This sugar fuels your body's cells, giving them the energy they need to work properly. You may need to take insulin if your pancreas has trouble making enough insulin, which is the case for people with type 1 diabetes and for some people who have type 2 diabetes.
Humulin 70/30 contains two different insulins, one that is intermediate-acting (NPH insulin) and one that is short-acting (regular insulin). It starts working quickly and continues to work for several hours.
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Humulin 70/30 [package insert]. Indianapolis, IN: Lily USA, LLC;2013 March.
Humulin 70/30 Vial [patient package insert]. Indianapolis, IN: Eli Lilly and Company;2007 August.
Humulin 70/30 Pen [patient package insert]. Indianapolis, IN: Eli Lilly and Company;2007 August.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed October 27, 2008.
Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 7th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2005.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click